Literature DB >> 11441433

Central effects of urotensin-II following ICV administration in rats.

J Gartlon1, F Parker, D C Harrison, S A Douglas, T E Ashmeade, G J Riley, Z A Hughes, S G Taylor, R P Munton, J J Hagan, J A Hunter, D N Jones.   

Abstract

RATIONALE: Urotensin-II (U-II) has recently been identified as an agonist for the G-protein-coupled receptor, GPR14. Detection of both U-II and GPR14 mRNA in the brain and spinal cord is consistent with a role for U-II in the CNS. However, the effects of central administration of U-II in rodents have not been reported previously.
OBJECTIVES: To determine the localisation of GPR14 mRNA in rat tissues and to investigate the behavioural and endocrine effects of human U-II (hU-II) following intracerebroventricular (ICV) administration in rats.
METHODS: Experiments were carried out in male Sprague-Dawley rats. Expression of GPR14 mRNA in rat brain was determined by semi-quantitative RT-PCR. Effects of hU-II on general behaviours were assessed by an observer and the motor activity response was measured by an automated activity monitor. Plasma hormones and [DOPAC + HVA]/[DA] and [5-HIAA]/[5-HT] ratios in five brain areas were measured 20 min post-hU-II (ICV).
RESULTS: GPR14 mRNA expression was found in whole brain tissue and in all CNS regions tested. GPR14 mRNA expression was also detected in the periphery; highest levels were found in the heart. Following ICV administration, hU-II (3-10 micrograms ICV) increased rearing and grooming, and increased motor activity in a familiar environment. Further, hU-II increased plasma prolactin and TSH but did not affect levels of corticosterone. hU-II had no effects on dopamine or 5-HT levels or their metabolites in the frontal cortex, hippocampus, hypothalamus, striatum and nucleus accumbens.
CONCLUSIONS: These data provide further insight into the distribution of GPR14 mRNA within the CNS and show for the first time that hU-II causes marked behavioural and endocrine effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11441433     DOI: 10.1007/s002130100715

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 2.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

Review 3.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

4.  Behavioral effects of urotensin-II centrally administered in mice.

Authors:  Jean-Claude Do-Rego; David Chatenet; Marie-Hélène Orta; Bertrand Naudin; Camille Le Cudennec; Jérôme Leprince; Elizabeth Scalbert; Hubert Vaudry; Jean Costentin
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

5.  Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Authors:  Raffaella Vergura; Valeria Camarda; Anna Rizzi; Martina Spagnol; Remo Guerrini; Girolamo Calo'; Severo Salvadori; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

6.  Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the βγ subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C β1 isoform.

Authors:  Yuan Zhang; Jiaoqian Ying; Dongsheng Jiang; Zhigang Chang; Hua Li; Guoqiang Zhang; Shan Gong; Xinghong Jiang; Jin Tao
Journal:  J Biol Chem       Date:  2015-02-12       Impact factor: 5.157

7.  Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.

Authors:  Nabil A Elshourbagy; Stephen A Douglas; Usman Shabon; Stephen Harrison; Graham Duddy; Jan L Sechler; Zhaohui Ao; Beverly E Maleeff; Diane Naselsky; Jyoti Disa; Nambi V Aiyar
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

8.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells.

Authors:  Eugen Brailoiu; Xiaohua Jiang; G Cristina Brailoiu; Jun Yang; Jaw Kang Chang; Hong Wang; Nae J Dun
Journal:  Peptides       Date:  2008-01-31       Impact factor: 3.750

10.  Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.

Authors:  Stephen A Douglas; Diane Naselsky; Zhaohui Ao; Jyoti Disa; Christopher L Herold; Frank Lynch; Nambi V Aiyar
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.